Where do we land on GLP-1s after three years of normalization?
When Ozempic hit cultural saturation in 2023, the discourse was 99% "is this a miracle weight-loss drug" and 1% "what are the long-term effects." We've now had enough time for the second question to start producing real answers.
What I'm seeing in the 2026 picture:
- Generic versions in some markets have pushed retail price below $50/month
- Muscle-mass loss is real and is now the subject of pharma R&D on combination therapies
- The cardiovascular benefits are increasingly recognized as the primary clinical justification rather than weight loss
- Cultural backlash exists but is much smaller than the 2024 "ozempic face" cycle suggested it would be
What didn't materialize:
- The "GLP-1s kill the diet industry" thesis. The diet industry pivoted hard into being adjuncts (resistance-training programs marketed at GLP-1 users) and seems fine
- The food-and-beverage demand collapse. Snack-food sales dipped briefly in 2024 and have largely recovered
For people who've been on these or watched the data closely — what's been the most surprising development?
5 replies
The muscle-mass loss issue is bigger than the public narrative suggests. The new combination therapies (GLP-1 + activin receptor antagonist) are still in trials but the early Phase 3 numbers are good. Watch this space for 2027.
Cardiovascular benefits being the primary justification is the right framing. The weight loss is a side effect of a metabolic intervention, not the point. Public discourse still hasn't caught up to this.
Diet industry pivot was textbook adaptation. Same companies, different products. Curves → F45 → GLP-1 strength training. Each cycle is shorter than the last.
Generic GLP-1s in India, Brazil, parts of SE Asia are even cheaper than $50/mo. Price collapse is faster than US insurers' formulary updates can keep up.
The 'ozempic face' cycle was largely a media confection. Real adverse effects exist (GI, gallbladder, muscle) but the visible cosmetic story was overblown to fill column inches.